Poor sales and pandemic blamed for Lumoxiti U-turn

11 December 2020

Shares in French biotech Innate Pharma (Euronext: IPH) dropped 20% on Friday morning, after the firm announced it was handing back US and European Union commercialization rights for Lumoxiti (moxetumomab pasudotox-tdfk).

UK pharma major AstraZeneca (LSE: AZN) out-licensed the Food and Drug Administration-approved product, an antibody-drug conjugate, to Innate in October 2018.

AstraZeneca has continued to pursue a broad commercialization strategy, submitting for marketing authorization in Europe in late 2019.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK